23andMe Regains Compliance With Nasdaq Listing Requirements
30 Octubre 2024 - 3:00PM
23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a
leading human genetics and preventive health company, today
announced that the Company has regained compliance with the minimum
closing bid price requirement under Nasdaq Listing Rule 5550(a)(2)
and the majority independent board and various board committee
requirements under Nasdaq Listing Rule 5605. Accordingly, the
Company's Class A common stock will continue to be listed on The
Nasdaq Capital Market and trade under the symbol “ME”.
About 23andMe23andMe is a genetics-led consumer
healthcare and biopharmaceutical company empowering a healthier
future. For more information, please visit www.23andMe.com.
Contactpress@23andme.cominvestors@23andme.com
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. All statements,
other than statements of historical fact, included or incorporated
in this press release are forward-looking statements. The words
“believes,” “anticipates,” “estimates,” “plans,” “expects,”
“intends,” “may,” “could,” “should,” “potential,” “likely,”
“projects,” “predicts,” “continue,” “will,” “schedule,” and “would”
or, in each case, their negative or other variations or comparable
terminology, are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are predictions
based on 23andMe’s current expectations and projections about
future events and various assumptions. 23andMe cannot guarantee
that it will actually achieve the plans, intentions, or
expectations disclosed in its forward-looking statements and you
should not place undue reliance on 23andMe’s forward-looking
statements. These forward-looking statements involve a number of
risks, uncertainties (many of which are beyond the control of
23andMe), or other assumptions that may cause actual results or
performance to differ materially from those expressed or implied by
these forward-looking statements. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company’s
filings with the Securities and Exchange Commission, including
under Item 1A, “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K, as filed with the Securities and Exchange
Commission, and as revised and updated by the Company’s Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K. The
statements made herein are made as of the date of this press
release and, except as may be required by law, the Company
undertakes no obligation to update them, whether as a result of new
information, developments, or otherwise.
23andMe (NASDAQ:ME)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
23andMe (NASDAQ:ME)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024